R.A. (Rudolf) de Boer
Cardiologist & Head Experimental Cardiology
Telephone:
+31 50 361 5340 (Laboratory)
+31 50 361 2355 (Clinical Department)
+31 50 361 5525 (fax)
+31 50 361 1347 (fax)
E-mail:
r.a.de.boer umcg.nl
Field/Discipline
Expertise
Heart Failure
Translational cardiology
Translational cardiology
Other positions
Dutch Society of Cardiology, President-elect (2021-2023)
ESC, Heart Failure Association (HFA), Board member Basic Section (2014-2020)
Fellow of the European Society of Cardiology (FESC, 2010 - onwards)
ESC Council on Cardio-Oncology, Liaison Officer (2020-2022)
Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
Project leader, research project heart failure, sponsored by Cardior GmbH
Project leader, research project heart failure, sponsored by Ionis Pharmaceuticals, Inc.
Project leader, research project heart failure, sponsored by Boehringer Ingelheim
Project leader, research project heart failure, sponsored by Roche Diagnostics
Project leader, grant European Research Council (ERC CoG 818715, SECRETE-HF)
Project leader, grant Netherlands Heart Foundation, CVON DOUBLE DOSE, grant 2020B005
Project leader, grant Netherlands Heart Foundation, CVON SHE-PREDICTS-HF, grant 2017-21
Project leader, grant Netherlands Heart Foundation, CVON RED-CVD, grant 2017-11
PI, grant Netherlands Heart Foundation, CVON PREDICT2, grant 2018-30
PI, grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)
Speaker fee, Bayer AG
Speaker fee, BIAL
Speaker fee, Novartis Pharma
Member Executive Committee of the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) clinical trial
Co-PIof the Hemodynamic Monitoring with the CardioMEMS PA sensor and Quality of Life in Patients with Chronic Heart Failure (MONITOR-HF) study
PI CARDIATEAM (Cardiomyopathy in type 2 diabetes mellitus), IMI MI2 - agreement number 821508
Member working group guideline Heart Failure, Dutch GP Society (NHG)
ESC, Heart Failure Association (HFA), Board member Basic Section (2014-2020)
Fellow of the European Society of Cardiology (FESC, 2010 - onwards)
ESC Council on Cardio-Oncology, Liaison Officer (2020-2022)
Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
Project leader, research project heart failure, sponsored by Cardior GmbH
Project leader, research project heart failure, sponsored by Ionis Pharmaceuticals, Inc.
Project leader, research project heart failure, sponsored by Boehringer Ingelheim
Project leader, research project heart failure, sponsored by Roche Diagnostics
Project leader, grant European Research Council (ERC CoG 818715, SECRETE-HF)
Project leader, grant Netherlands Heart Foundation, CVON DOUBLE DOSE, grant 2020B005
Project leader, grant Netherlands Heart Foundation, CVON SHE-PREDICTS-HF, grant 2017-21
Project leader, grant Netherlands Heart Foundation, CVON RED-CVD, grant 2017-11
PI, grant Netherlands Heart Foundation, CVON PREDICT2, grant 2018-30
PI, grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)
Speaker fee, Bayer AG
Speaker fee, BIAL
Speaker fee, Novartis Pharma
Member Executive Committee of the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) clinical trial
Co-PIof the Hemodynamic Monitoring with the CardioMEMS PA sensor and Quality of Life in Patients with Chronic Heart Failure (MONITOR-HF) study
PI CARDIATEAM (Cardiomyopathy in type 2 diabetes mellitus), IMI MI2 - agreement number 821508
Member working group guideline Heart Failure, Dutch GP Society (NHG)
| Last modified: | 01 March 2024 12.17 p.m. |